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A protocol to determine valid ?̇?O2max in young cystic fibrosis patients  
 
 
 
 
 
Abstract 
Objectives: Measuring aerobic fitness (V̇O2max) via a maximal cardiopulmonary exercise test (CPET) 
is an important clinical tool in cystic fibrosis (CF). This study sought to establish: (1) the validity of 
traditional criteria to verify maximal efforts during a ramp CPET; and (2) whether V̇O2 measured 
during an exhaustive CPET represents a valid V̇O2max in paediatric patients, using a subsequent 
exhaustive supramaximal (Smax) exercise test. Design. Cross-sectional. Method: Fourteen patients (7-
18 y; 10 male) completed an exhaustive ramp test to determine V̇O2max. Following 15-min recovery, 
Smax (110% ramp peak power output) was performed. Results: Ramp test V̇O2peak was significantly 
higher than V̇O2 documented at traditional endpoint criteria, including a RER of 1.00 (0.99 ± 0.47 vs. 
1.83 ± 0.78 L·min
-1
, p < 0.001) and 1.10 (1.36 ± 0.59 vs. 1.83 ± 0.78 L·min
-1
, p < 0.001), despite 
100% of patients satisfying these two criteria. Only 23% and 75% of patients satisfied the 95% age-
predicted heart rate (HR) maximum and 180 beats·min
-1
 criteria. Whilst mean ramp and Smax V̇O2peak 
were not significantly different (1.83 ± 0.78 vs. 1.82 ± 0.67 L·min
-1
; p = 0.88), at the individual level 
Smax elicited a ‘meaningful’ (> 9%) increase in V̇O2peak (range 9.9 – 38.3%) compared with V̇O2peak 
from the ramp test in 3 of 14 cases (21.4%). Conclusions: Traditional criteria significantly 
underestimate V̇O2max in young CF patients. Conversely, Smax can confirm when ‘true’ V̇O2max is 
achieved. The use of Smax following CPET represents an appropriate method to measure V̇O2max in 
young CF patients.  
 
 
Key words: Exercise test; cystic fibrosis; supramaximal verification; physical fitness; paediatric 
physician; lungs. 
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Introduction 
 
Exercise testing is a valuable investigative tool in young people with chronic diseases, such as cystic 
fibrosis (CF). Although lung function traditionally measures disease severity, it cannot accurately 
predict exercise capacity
17,24
. Current standards for CF management therefore recommend at least 
annual exercise testing
10
, however current provision is unsatisfactory
4,24
. Cardiopulmonary exercise 
testing (CPET), incorporating measurement of pulmonary gas exchange, provides the most precise 
measure of exercise capacity [maximal oxygen uptake (V̇O2max)] in mild-to-moderate CF. 
Furthermore, V̇O2max holds suggested value in prognostic stratification of patients
17
.  
  
V̇O2max represents the integrated capacity of the pulmonary, cardiovascular and muscular systems to 
uptake and utilise O2 during intense exercise and is traditionally identified by a V̇O2 plateau upon 
exhaustion despite an increasing work rate
20
. Since only a minority of young people display this 
response
20,4,2
, the term V̇O2peak is commonly used, defined as the highest V̇O2 attained during an 
exhaustive test
4
. To verify a ‘maximal effort’, reliance therefore falls upon secondary criteria, 
encompassing subjective indicators of effort (sweating, facial flushing, hyperpnoea) and objective 
secondary criteria (heart rate (HR), respiratory exchange ratio (RER) and/or blood lactate 
concentration (La[B])). Unfortunately, most previous studies in CF have not specified their verification 
criteria. In those which have, there is some disparity, with objective criteria including RER >1.00
13,15
 
and >1.10
17
 and HRs of 180 beats per minute
13,15
 and 95% of age-predicted maximum
25,26
. Such 
criteria are dependent on arbitrary values which often underestimate ‘true’ V̇O2max and have thus been 
deemed invalid for healthy children
4
 and young spina bifida patients
11
. It is conceivable that 
secondary criteria are equally unsuitable for young CF patients. Documenting a valid V̇O2max is crucial 
to the clinical utility of CPET within CF. Accepting submaximal values could distort clinical 
interpretation and underestimate patients’ prognosis, influencing decisions regarding clinical 
intervention and/or exercise prescription.   
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It is important that new conceptual advances within exercise physiology continue to be incorporated 
within clinical practice. A procedure termed the ‘verification phase’, where CPET is followed by an 
individualised supramaximal ‘step’ test to exhaustion (Smax), can ensure the valid determination of 
V̇O2max in healthy children
4
, sedentary adults
3
, active middle-aged and older adults
19,9
 and adolescent 
spina bifida patients
10
. Supramaximal exercise denotes exercise above the highest peak power 
achieved during a preceding exhaustive CPET. While Smax has been safely implemented in paediatric 
spina bifida patients
11
 and patients with chronic heart failure
8
, the utility, safety and feasibility for 
young CF patients is unknown. The study aimed to establish the validity of CPET derived V̇O2max and 
the utility of Smax to provide a robust measure of V̇O2max in young CF patients. We hypothesised that: 
1) traditional verification criteria would significantly underestimate ‘true’ V̇O2max; and 2) the V̇O2max 
obtained during a traditional incremental ramp test would not significantly differ to that from a 
subsequent Smax verification test, thus providing a valid measure of V̇O2max.  
 
Methods 
Fourteen young patients (Table 1) with mild-to-moderate CF, regularly partaking in physical activity 
as is suggested by clinical disease management guidelines, participated in this study. Inclusion criteria 
comprised a diagnosis of CF based on clinical features, an abnormal sweat test (sweat chloride > 60 
mmol·L
-1
 / 100 mg sweat) and genotyping. Stable lung function within 10% of best in the preceding 6 
months and no symptomatic increase or weight loss within 2 weeks was mandatory. Unstable non-
pulmonary comorbidities and/or acute infection warranted excluded. Disease severity was graded 
using the Schwachman score (SS) as part of patients’ annual clinical review (Table 1). Ethical 
approval was granted by the South West NHS Research Ethics Committee and informed written 
consent and assent obtained from parents/guardians and patients, respectively. Body mass was 
measured to the nearest 0.01 kg and stature to the nearest 0.01 m. Pulmonary function, assessed via 
spirometry (MicroMedical MicroLoop 3535), determined forced vital capacity (FVC) and forced 
expiratory volume in 1-s (FEV1) (Table 1). Pubertal staging was self-assessed (boys ≥10 and girls ≥8 
y) according to pubic hair classification
28
 (Table 1) following testing.  
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Exercise was performed on cycle ergometers [Lode Excalibur, Groningen, The Netherlands; Lode 
(paediatric)]. Following 3-min warm-up (20 W), patients completed an incremental ramp test, 
whereby resistance increased at a predetermined rate (10-25 W∙min-1), ensuring ~8-12 min durations. 
Patients maintained ~70-80 rpm until volitional exhaustion, defined as a drop in cadence >10 rpm for 
5 consecutive seconds despite strong verbal encouragement. Peak power output was recorded upon 
exhaustion. Five minutes warm-down (20 W) and 10-min seated recovery followed. Smax was 
subsequently undertaken, whereby 3-min cycling (20 W) preceded a ‘step’ transition to a constant 
work rate equivalent to 110% of peak power output. This work rate was maintained until exhaustion, 
followed by 5-min recovery (20 W).  
 
Gas analysers were calibrated using gases of known concentration, and the turbine volume transducer 
using a 3 L calibration syringe (Hans Rudolph, Kansas City, MO). Breath-by-breath pulmonary gas 
exchange and ventilation (Metalyzer 3B Cortex, Biophysik, Leipzig, Germany; Metasoft v.3.9.7) were 
measured using a face mask and, following 1-s interpolation, averaged to 15-s time bins which was 
subsequently used for all parameters. When appropriately calibrated the accuracy of measuring 
volume and gas fractions are 2% and 0.1%, respectively. The highest 15-s stationary average 
represented V̇O2peak. HR was determined at 5-s intervals (PhysioFlow, PF-05, Manatec Biomedical, 
Paris, France) and peak HR (HRpeak) taken as the highest 15-s mean value. Transcutaneous O2 
saturation (SpO2%) was determined on a beat-by-beat basis via pulse oximetry (Avant 4000, 
NONIN Medical Inc., USA). A fingertip capillary blood sample (~5 µL) was taken within 30-s of 
exhaustion following the ramp and analysed for La[B] (Lactate Pro, Arkray, Japan). Subjective ratings 
of perceived exertion (RPE) and dyspnoea (RPD) were recorded upon exhaustion using the pictorial 
children’s effort rating table (P-CERT)12 and the 0-10 category-ratio (CR-10) scale7, respectively. 
 
The presence of a V̇O2 plateau was determined using methodology more comprehensively described 
elsewhere
10,19
. Briefly, analysis requires a linear regression over the ‘linear’ portion of the VO2 
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response. The V̇O2 profile at exhaustion was subsequently characterised by extrapolating this linear 
regression function to exhaustion and isolating the final 60-s of data to examine the residuals against 
the extrapolated line. A negative residual indicated a deceleration in V̇O2 against power output and 
was considered a ‘plateau’ when the magnitude of the residuals was ≥ 5% of the projected V̇O2 (i.e. 
V̇O2 was ≤ 95% of the projected V̇O2). A positive residual ≥ 5% of the projected V̇O2 represented 
acceleration and positive or negative residuals <5% of the peak power output projected V̇O2 were 
categorised as a linear responses
21
. Secondary verification criteria (V̇O2 at an RER of 1.00
13,15
 and 
1.10
16
, a HR of 180 b∙min-1 13,15 and 95% age-predicted HRmax
25,26
 were selected within the current 
study based on their use within CF patients, whilst La[B] ≥ 6 mmol∙L
-1
 is often utilised in paediatric 
studies. 
 
Data are expressed as means and standard deviations unless otherwise stated and significance set at p 
< 0.05. Paired samples t-tests determined mean differences between ramp and Smax V̇O2peak. Linear 
regression and Bland and Altman limits of agreement analysis
6
 (mean bias and 95% confidence limits 
[95% CL]) examined the agreement between ramp and Smax V̇O2peak. A greater than 9% increase was 
considered a ‘meaningful’ change between ramp and Smax derived V̇O2peak. This value is considered 
the typical within-subject short-term variation of V̇O2max in paediatric CF patients, established using 
unpublished data from within our laboratory. Analyses were performed using SPSS v.18.0 (Chicago, 
Illinois, USA) and GraphPad Prism (GraphPad Software Inc., San Diego, California, USA).  
 
Results 
Mean ramp test duration was 9 min 27 s ± 3 min 16 s, resulting in a peak power output of 174 ± 84 
W. Mean V̇O2peak was 1.83 ± 0.78 L·min
-1
 (34.23 ± 6.57 mL∙kg-1∙min-1). Ramp V̇O2peak was not 
significantly different to the V̇O2peak predicted by the linear extrapolation of the V̇O2-power output 
relationship (1.83 ± 0.84 L·min
-1
; p = 0.99). Mean goodness of fit (R
2
) for the linear function was 0.84 
± 0.19.  Analysis of patients’ V̇O2-power output profiles revealed a single plateau upon exhaustion, 
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with 13 patients characterised by a linear V̇O2 response (Table 2).  The mean ‘gain’ (ΔV̇O2/ΔWR) of 
patients’ V̇O2 response to the ramp was 7.81 ± 1.57 mL∙min
-1∙W-1. 
 
All patients satisfied the RER > 1.00 and >1.10 criteria (Table 2). However, the V̇O2 at a RER of 1.00 
(0.99 ± 0.47 L·min
-1
) was lower than that recorded at exhaustion (1.83 ± 0.78 L·min
-1
; p < 0.001), 
representing only 54% of V̇O2peak. Similarly, the V̇O2 at RER of 1.10 (1.36 ± 0.59 L·min
-1
; p < 0.001) 
were lower than V̇O2 upon exhaustion, representing only 74% of V̇O2peak. Bland and Altman analysis 
demonstrated the RER of 1.00 and 1.10 criteria to underestimate V̇O2max by a mean bias of –1.10 
L·min
-1
 (95% CL: -1.68 to -0.01 L·min
-1
, Figure 1a) and -0.47 L·min
-1
 (95% CL: -1.02 to 0.08 L·min
-
1
, Figure 1b), respectively. Mean La[B] following the ramp was 9.5 ± 13.1 mmol∙L
-1
 (n = 13). Ten 
patients satisfied the ≥ 6 mmol∙L-1 criteria (Table 2).   
 
Due to data loss, HR is presented for 12 patients with a HRpeak of 188 ± 12 b·min
-1
. Nine patients 
satisfied achieved 180 b·min
-1
 (Table 2), whilst 3 attained 95% age-predicted maximum (equating to 
196 ± 2 beats∙min-1; Table 2). In those patients satisfying the HR criteria, V̇O2 at 180 beats·min
-1
 (1.75 
± 0.60 L·min
-1
) and 95% of their age-predicted maximum (1.72 ± 0.50 L·min
-1
) was lower than that 
recorded upon exhaustion (1.98 ± 0.84 and 2.04 ± 0.53 L·min
-1
, respectively), representing 88% and 
84% of V̇O2peak, respectively. Bland and Altman analysis revealed 180 beats·min
-1
 and 95% age-
predicted maximum criteria to underestimate V̇O2max by a mean bias of -0.23 L·min
-1
 (95% CL: -0.85 
to 0.39 L·min
-1
; Figure 1c) and -0.32 L·min
-1
 (95% CL: -0.46 to -0.18 L·min
-1
), respectively. 
 
Mean Smax duration was 1 min 23 s ± 0 min 20 s and elicited a similar V̇O2peak to the ramp, despite 
exercising at a higher power output (191 ± 93 W, Table 3). Bland Altman analysis for ramp and Smax 
V̇O2peak revealed a mean bias of -0.00 L·min
-1
 (95% CL: -0.46 to 0.46 L·min
-1
) or 1.0% (95% CL: -
22.5% to 24.5%). No significant differences were observed for HRpeak, end-exercise SaO2%, RPE or 
RPD during ramp and Smax testing (Table S1).  
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Smax increased V̇O2peak above ramp V̇O2peak in 7 patients (50%) (Table 4; Figure 2), 3 (21%) of which 
were deemed clinically important rises (i.e. >9 % change). Based on this criterion, Smax confirmed a 
valid V̇O2max in 11/14 (79%) patients and identified 3 (21%) cases where a ‘true’ V̇O2max was not 
obtained, with an average V̇O2 increase of 20.3 ± 15.7% or 0.33 ± 0.21 L·min
-1
. No significant 
relationship existed between Smax duration and the difference between the ramp and Smax V̇O2peak 
(r=0.29; p=0.32).    
 
Discussion 
This study sought to establish the validity of traditional V̇O2max verification criteria and establish the 
utility of Smax in young CF patients. Results revealed four principle findings: 1) a V̇O2 plateau is rarely 
observed upon exhaustion; 2) adherence to secondary traditional criteria underestimates V̇O2max; 3) in 
most cases (78.6%), Smax did not increase V̇O2peak thus confirming a valid V̇O2max; and 4) Smax 
identified those whose initial CPET V̇O2peak was not a ‘true’ maximum. These findings have 
significant implications for the assessment and interpretation of CPET in young CF patients in a 
clinical and research setting.  
 
In this study only one V̇O2 plateau was documented upon exhaustion during CPET. While this is the 
first study to document the V̇O2 profile of young CF patients during ramp exercise, Werkman et al.
30
 
recorded a plateau in 5 of 16 adolescents with CF during step exercise to exhaustion. However, the 
latter study employed a fixed V̇O2 plateau criterion (< 2.1 mL·kg
-1
·min
-1
), which was originally 
developed on adults during a discontinuous running protocol consisting of steady-state stages
29
 and is 
unlikely to account for the altered O2 cost of exercise reported in young CF patients
16
. This was 
accounted for in our study, using an extrapolated linear function from each participant’s V̇O2-power 
output profile prior to exhaustion. Our findings indicate that young CF patients rarely satisfy the 
conventional criteria of a V̇O2 plateau during CPET.  
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Secondary criteria have therefore been adopted to verify V̇O2max in young people, however they often 
underestimate V̇O2max or reject a ‘true’ measure within healthy children
20,4
. Such criteria may be 
equally unsuitable for clinical paediatric populations. The present investigation confirms this notion. 
Achieving an RER > 1.00 was the least robust criterion, underestimating on average by 46% (Figure 
1a). Achieving a RER > 1.10, 180 beats·min
-1
 (Figure 1c) and 95% of age-predicted HRmax 
underestimated V̇O2max by an average of 26%, 12% and 16%, respectively. Although HR criteria 
appear more robust, their use is limited as five patients (36%) failed to achieve a HR of 180 
beats·min
-1
, and eleven (79%) failed to achieve 95% of their age-predicted HRmax, one of whom 
exhibited a V̇O2 plateau. Given the emerging evidence base to reject secondary criteria in healthy 
children
4,20
 and adults
18
 and now young CF patients, their use as a verification tool is limited and 
should be discontinued.  
 
Smax verification ensures that if the V̇O2peak obtained during a CPET is ‘truly’ maximal, then 
performing exercise above peak power output from a preceding ramp test should not elicit a further 
increase in V̇O2, thus satisfying the primary plateau criterion. Limited application of Smax in clinical 
populations is plausible, as poor exercise tolerance and slow V̇O2 kinetics
14
 may preclude the 
attainment of V̇O2max. The present study has demonstrated, however, that Smax can verify V̇O2max in CF. 
Additionally, mean Smax duration was 85 ± 26 s, which is comparable with healthy children (91 ± 26 
s) exercising at 105% peak power
4
. No adverse incidents were encountered, substantiating previous 
reports that exercise testing is safe in mild-to-moderate CF
21
.  
 
Although mean Smax V̇O2peak was comparable with traditional ramp testing, Smax elicited meaningful 
rises in 3 of 14 (21%) cases (range 9.9-38.3%; Figure 2), findings comparable to young spina bifida
11
 
[5 of 20 (33%)] and adult chronic heart failure (21%)
8
 patients. In healthy children, Smax increased 
V̇O2peak (potentially negligible) in only 1 of 13 cases (8%)
4
. These findings support Smax as a safe and 
powerful tool in CF patients to validate V̇O2max measurement.  
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Werkman et al.
30
 recently examined the feasibility of a steep ramp test (SRT) to verify V̇O2max in 
adolescent CF patients. The authors concluded that V̇O2peak from traditional CPET reflected ‘true’ 
V̇O2max. Although, not discussed by these authors, it is clear that 4 of their 13 patients experienced a 
potentially meaningful rise in V̇O2 during the SRT (see figure 2, page 19), which is comparable to the 
Smax increase in V̇O2peak herein. This supports the present findings that Smax confirmation is an essential 
addition to traditional CPET to confirm a ‘true’ V̇O2max in young patients with cystic fibrosis.  
 
Individual patient data is of interest to the clinician, in that those with the greatest increase in V̇O2max 
resulting from Smax were patients about whom there were treatment adherence concerns (e.g. patients 
3 and 14). Conversely, those with lower Smax V̇O2peak versus the ramp were typically physically active 
and more accomplished in sporting activities (e.g. patients 1 and 6). Although patients 3 and 14 
possessed slightly lower V̇O2peak scores when expressed relative to body mass, their lower fitness are 
unlikely solely attributable to more severe disease, since superior fitness was recorded for a number of 
patients with lower scores on all aspects of the disease profile (Table 1). Their scores likely represent 
poor motivation during CPET which may be indicative of motivation in other aspects of their disease 
management.  
 
Combining a traditional ramp CPET with a Smax test permits the identification of a valid V̇O2max. This 
protocol can be safely and effectively undertaken within a single laboratory visit and offers clear 
guidelines and a superior validation of V̇O2max than current methods. To utilise V̇O2max in prognostic 
stratification
17
, it is essential that ‘true’ measurements are obtained. Accepting submaximal or 
rejecting ‘true’ values could distort clinical application and interpretation. Since healthy adults do not 
always plateau, Smax may be useful for adult CF patients. However, as more severe disease is 
associated with aging in CF, the safety and tolerance of Smax in older patients warrants investigation. 
Whether a further Smax test, at a higher percentage of peak power output, could verify V̇O2max in the 
cases where V̇O2peak increased significantly is also unknown, although utility of a subsequent, more 
intense verification test to verify V̇O2max has been demonstrated in healthy adults
22
. From a practical 
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viewpoint, Smax verification is straightforward to implement as the imposed power output is calculated 
from ramp test peak power output on an individual basis and, clinically, may minimise the costs 
associated with re-tests when the validity of test results is questionable.  
 
Conclusion 
In conclusion, Smax verification is a safe and well-tolerated tool to determine valid V̇O2max in young 
CF patients. Although the present uptake of CPET is poor within the clinical management of young 
people with mild-to-moderate CF
24,5
, the European CF Society (ECFS) Exercise Working Group have 
recently recognised such testing as the method of choice when assessing aerobic fitness in this patient 
population. Consequently, it is recommended that Smax verification replace traditional criteria for 
confirming a ‘true’ V̇O2max measurement in young CF patients with mild-to-moderate disease.  
 
Practical implications:  
 Aerobic fitness (V̇O2max) measurement can help predict survival in cystic fibrosis.    
 Criteria commonly used to confirm V̇O2max tend to underestimate ‘true’ fitness. Conversely, a 
‘supramaximal’ exercise test can confirm ‘true’ measurements.  
 Underestimating V̇O2max could result in incorrect interpretation of patients’ fitness, prognosis 
and/or the influence of a therapeutic intervention.  
 It is recommended that Smax be adopted when performing CPET on young CF patients in the 
clinical or research environments.   
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Tables 
 
Table 1. Patients’ baseline anthropometric and clinical data.  
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Patient 
(Gender) 
Pubertal
maturity 
Age  
(years) 
Stature (m) Body mass 
(kg) 
BMI 
(kg·m
2
) 
CFTR genotype C. 
PSA
a 
SS Northern  
score
b 
FVC 
[% predicted (L)] 
FEV1 
[% predicted (L)] 
1 (M) 3 13.4 164.9 62.1 23.1 ∆ F508 /∆F508 I 85 4 127  (4.58) 120  (4.07) 
2 (M) 4 16.7 177.0 85.0 29.4 ∆ F508 /∆F508 F 87 4 112  (4.95) 87  (3.60) 
3 (M) 4 13.4 167.9 69.7 24.1 ∆ F508/P67L F 80 3 101  (3.57) 112  (3.04) 
4 (F) 1 7.6 123.6 24.0 16.1 ∆ F508 /621+IG    T F 89 3 112  (1.62) 108 (1.43) 
5 (M) 4 9.9 141.2 41.8 21.1 ∆ F508 /∆F508 C 85 4 106  (2.47) 93  (2.04) 
6 (M) 2 11.2 141.9 44.8 22.8 ∆ F508 /∆F508 F 79 5 96  (2.23) 65  (1.39) 
7 (M) 3 13.9 174.6 89.8 28.1 ∆ F508 /∆F508 I 82 4 123  (5.11) 97  (3.84) 
8 (F) 1 12.2 135.0 32.5 18.1 ∆ F508 / 2184delA N 81 3 125  (2.19) 101  (1.95) 
9 (M) 1 11.1 149.5 32.1 14.4 ∆ F508 /∆F508 I 67 6 79  (2.19) 67  (1.71) 
10 (M) 2 16.1 151.6 44.1 19.3 ∆ F508 /∆F508 F 75 3 93 (2.69) 69 (1.83) 
11 (M) 2 14.9 170.3 56.7 19.5 ∆ F508 / G55ID C 82 6 115  (4.55) 110 (4.06) 
12 (M) 1 7.8 135.1 43.6 25.0 ∆ F508 /∆F508 N 91 2 112  (2.40) 108  (1.92) 
13 (F) 2 16.6 166.0 65.0 25.0 ∆ F508 /∆F508 F 88 3 99  (3.46) 85 (2.95) 
14 (F) 4 18.4 172.0 58.0 20.2 ∆ F508 /∆F508 I 81 3 85  (3.53) 82 (2.98) 
Mean 
(SD) 
[range] 
2 
(1) 
[1-4] 
13.1 
(3.32) 
[7.57-18.4] 
1.5 
(0.17) 
[1.23-1.74] 
55.5 
(19.3) 
[24.4-87.9] 
21.9 
(4.31) 
[14.4-29.4] 
- 
- 
- 
- 
- 
- 
82 
(6) 
[67-91] 
4 
(1) 
[2-6] 
104; 3.30  
(15; 1.2) 
[79-127; 1.62-5.11] 
92; 2.66 
(18; 1.0) 
[65-120; 1.39-4.07] 
Values are means ± SD, with the range also displayed where suitable, unless otherwise stated. BMI, body mass index; CFTR, cystic fibrosis transmembrane conductance regulator; C. PSA, 
chronic Pseudomonas aeruginosa infection; I, intermittent; F, free; C, chronic; N, never; SS, Shwachman score - scoring 4 separate aspects of the disease profile; general activity; physical 
examination; nutritional status; and chest radiographic findings, using the most recent clinical review information. A total of 100 points represents a perfect score of health; FVC, forced vital 
capacity; FEV1, forced expiratory volume in 1 second. 
a
 According to Leeds Criteria, “chronic”, >50% of the preceding 12 months were P. aeruginosa culture positive; “intermittent”, ≤50% of 
the preceding 12 months were P. aeruginosa culture positive; “never”, no growth of P. aeruginosa for the previous 12 months, having previously been P. aeruginosa culture positive; “free”, P. 
aeruginosa has never been cultured. 
b
 Provides evidence of radiographic chest findings. Maximum score is 20, with 20 being the most severe.  
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Table 2. Ramp test responses in relation to traditional verification criteria.  
Patient Gender Age 
(y) 
Ramp 
VO2peak 
(L∙min-1) 
VO2 
plateau 
VO2 at 
RER >1.00 
(L∙min-1) 
VO2 at RER  
>1.10 
(L∙min-1) 
VO2 at 180 
b∙min-1 
(L∙min-1) 
VO2 at 95% age-
predicted HR 
(L∙min-1)  
La[B] ≥ 6 
mmol∙L-1
 
1 M 13.4 2.32 No 0.96 1.58 - - Yes 
2 M 16.7 3.78 Yes 2.30 3.09 2.76 N/A Yes 
3 M 13.4 2.05 No 0.79 1.23 1.94 N/A Yes 
4 F 7.6 0.84 No 0.47 0.73 N/A N/A DNC 
5 M 9.9 1.39 No 0.73 1.08 1.39 N/A No 
6 M 11.2 1.74 No 1.12 1.42 1.50 1.50 Yes 
7 M 13.9 2.16 No 1.25 1.53 - - Yes 
8 F 12.2 1.18 No 0.83 1.06 1.11 N/A Yes 
9 M 11.1 1.03 No 0.71 0.94 N/A N/A No 
10 M 16.1 1.72 No 0.96 1.45 1.45 1.37 Yes 
11 M 14.9 2.65 No 1.50 1.89 2.40 2.28 Yes 
12 M 7.8 1.11 No 0.83 0.79 1.02 N/A No 
13 F 16.6 2.16 No 0.75 1.32 2.16 N/A Yes 
14 F 18.4 1.49 No 0.71 0.96 N/A N/A Yes 
DNC, did not consent to blood sampling for assessment of end-exercise blood lactate concentration (La[B]); N/A, not achieved; - , Loss of PhysioFlow data. VO2peak, peak 
oxygen uptake; RER, respiratory exchange ratio; HR, heart rate (n=12); La[B], blood lactate concentration; ramp; incremental ramp test. 
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Table 3. Decision to accept ?̇?O2peak using a combined ramp and Smax exercise test 
 
Patient 
(Gender) 
Age 
(years) 
Ramp 
VO2peak 
(L·min-1) 
Smax 
VO2peak 
(L·min-1) 
∆Change 
(L·min
-1
) 
% 
Change 
True 
VO2max 
obtained? 
1 (M) 13.4 2.32 2.01 -0.31 -13.4 Yes (ramp) 
2 (M) 16.7 3.78 3.35 -0.43 -8.5 Yes (ramp) 
3 (M) 13.4 2.05 2.31 +0.26 +12.7 No 
4 (F) 7.6 0.84 0.89 +0.05 +6.0 Yes (Smax) 
5 (M) 9.9 1.39 1.41 +0.02 +1.4 Yes (Smax) 
6 (M) 11.2 1.74 1.57 -0.17 -9.8 Yes (ramp) 
7 (M) 13.9 2.16 1.99 -0.17 -7.9 Yes (ramp) 
8 (F) 12.2 1.18 1.11 -0.07 -5.9 Yes (ramp) 
9 (M) 11.1 1.03 1.10 +0.07 +6.8 Yes (Smax) 
10 (M)  16.1 1.72 1.89 +0.17 +9.9 No 
11 (M) 14.9 2.65 2.47 -0.18 -6.8 Yes (ramp) 
12 (M) 7.8 1.11 1.11 0 0 Yes (either) 
13 (F) 16.6 2.16 2.20 +0.04 +1.9 Yes (Smax) 
14 (F) 18.4 1.49 2.06 +0.57 +38.3 No 
 
V̇O2max, maximal oxygen uptake; ramp; incremental ramp test; Smax, supramaximal exercise test. 
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Supplementary Material 
 
Figure S1. Bland and Altman plots for the secondary criteria typically used during CPET of 
young CF patients. Plots show the mean bias (floating dotted line) and 95% confidence limits 
(floating dashed lines) for the oxygen uptake (V̇O2) recorded at an RER of ≥ 1.00 (A), an 
RER of ≥ 1.10 and (B) a heart rate of 180 beats·min-1 (C) compared with the actual V̇O2 
recorded at exhaustion from the traditional ramp test in absolute terms (top row) and as a 
percentage of the difference (bottom row).  
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S2. The agreement between the peak oxygen uptake (V̇O2peak) recorded at exhaustion during 
ramp and Smax testing. Plots show the mean bias (floating dotted line) and 95% confidence 
limits (floating dashed lines) for the V̇O2 recorded at exhaustion during ramp and Smax 
exercise in absolute terms (A) and as a percentage of the difference (B), according to Bland 
and Altman (1986).   
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Table S1. Peak physiological responses during the ramp and Smax tests  
 
 
 
Variable Ramp Smax p-
value 
V̇O2peak (L∙min
-1
) 1.83 ± 0.78  [0.84-3.77] 1.83 ± 0.69  [0.89-3.46] 0.98 
V̇O2peak (mL∙kg
-1∙min-1) 34.23 ± 6.57  [25.23-47.54] 34.46 ± 5.65  [23.32-
44.42] 
0.83 
RERpeak 1.29 ± 0.10  [1.15-1.49] 1.23 ± 0.12  [0.99-1.34] 0.07 
HRpeak (b∙min
-1
, n=12) 188 ± 12  [170-208] 183 ± 13  [158-201] 0.08 
SpO2% 96 ± 2   [90-99] 95 ± 3   [90-98] 0.19 
RPE 8 ± 2   [5-10] 8 ± 3   [4-10] 0.37 
RPD 6 ± 2   [2-10] 7 ± 3   [4-10] 0.26 
 
Values are means ± SD, with the range also displayed in parenthesis unless otherwise stated. 
V̇O2peak, peak oxygen uptake; RERpeak, peak respiratory exchange ratio; HRpeak, peak heart rate; SpO2%, end-
exercise arterial oxygen saturation; RPE, end-exercise rating of perceived exertion; RPD, end-exercise rating of 
perceived dyspnoea; ramp; incremental ramp test; Smax, supramaximal exercise test.  
 
 
 
 
 
 
 
 
 
 
 
 
